Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The gut microbiota can modulate the effectiveness of cancer therapies, especially
immunotherapy. Manipulating the microbial populations in patients with advanced lung cancer
through fecal microbiota transplantation from healthy individuals or from long-term survivors
to advanced lung cancer will enhance the efficacy of immunotherapy.
Phase:
N/A
Details
Lead Sponsor:
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal